Combination therapy of T-cell engager and chemotherapy for pancreatic cancer treatment - the american cancer society estimates that in 2025 approximately 67,440 new cases of pancreatic cancer will…
Active Grant Awarded
- Award ID
- R44CA306447
- Recipient
-
Oncotab, Inc. UEI E5FXNY7GG5M5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,130,587
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 17% complete
- Place of performance
- Charlotte, NC 28223, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Grant R44CA306447 to Oncotab, Inc. on July 17, 2026, obligating $1.130587 million under Assistance Listing 93.395, Cancer Treatment Research. The award is a Phase II Small Business Innovation Research (SBIR) grant to advance MUCD3, a bispecific T-cell engager that the recipient developed under prior Phase I awards, toward first-in-human trials for pancreatic cancer in combination with nab-paclitaxel (Abraxane) and gemcitabine. Funded activities include testing MUCD3's structural stability in mouse serum at 37 C, pharmacokinetic studies in HuCD34-NSG and FcRn mice, efficacy assessment in four TMUC1-positive patient-derived xenograft orthotopic models, cytokine release assays in human samples, and a maximum tolerated dose study in non-human primates. The period of performance runs from the July 17, 2026 award date to an ultimate completion date of July 31, 2028, with place of performance in Charlotte, NC 28223.
Description
Combination therapy of T-cell engager and chemotherapy for pancreatic cancer treatment - the american cancer society estimates that in 2025 approximately 67,440 new cases of pancreatic cancer will be diagnosed in the united states, with 51,980 deaths. Nearly 80% of patients present with locally unresectable or metastatic disease, where the 5-year survival rate is as low as 3%. Standard first-line regimens-folfirinox (5- FU, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus NAB-paclitaxel (ABRAXANE)-achieve median overall survival (MOS) of up to 21 months, yet outcomes remain dismal, underscoring the urgent need for novel therapeutic strategies. Advances in antibody engineering have enabled bispecific antibodies (BSABS) that engage T cells and redirect them toward tumors. In our prior phase I awards, we developed a panel of bsab T-cell engagers and identified MUCD3 as the lead candidate. Preclinical studies demonstrated that MUCD3 slowed tumor growth as monotherapy and, when combined with ABRAXANE and gemcitabine, significantly inhibited chemotherapy-resistant pancreatic tumors. Importantly, the combination also reduced cytokine release, a common limitation of T-cell engagers. In this phase II sbir proposal, we will advance MUCD3 through key preclinical studies designed to DE-risk its path toward first-in-human (FIH) trials and eventual commercialization. MUCD3, produced from lonza-generated stable cell pools, will first be evaluated for structural stability in mouse serum at 37 °C, followed by pharmacokinetic studies in HUCD34-NSG and fcrn mice to guide dosing strategies. Efficacy will be assessed in four TMUC1- positive patient-derived xenograft (PDX) orthotopic models spanning a range of expression levels. In parallel, cytokine release assays in human samples and a maximum tolerated dose (MTD) study in non-human primates will establish the safety margin of MUCD3 in combination with NAB-PTX and gemcitabine. These animal models are essential to evaluate the in vivo pharmacokinetics, tumor-targeting efficacy, and safety of MUCD3 within an intact biological system, which cannot be fully replicated using in vitro approaches. We will collaborate with DR. TIM pardee (atrium health wake forest baptist), DR. Michael morse (duke health), and DR. Mohamed salem (levine cancer institute, atrium health), whose expertise in clinical oncology and trial design will guide execution of these studies and the design of the FIH trial. We anticipate that MUCD3, combined with ABRAXANE and gemcitabine, will demonstrate enhanced efficacy with reduced toxicity compared to current chemotherapy, offering the potential to meaningfully improve survival and quality of life for pancreatic cancer patients
Quick answers
Who received award R44CA306447?
R44CA306447 was awarded to Oncotab, Inc. by National Cancer Institute (National Institutes of Health) on July 17, 2026.
How much is award R44CA306447 worth?
$1,130,587 has been obligated on R44CA306447.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award